Correction to: Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy

Correction to: Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy

Bibliographic Details
Main Authors:	Wei Jiang, Lulu Wei, Bing Chen, Xingyu Luo, Peipei Xu, Jianfeng Cai, Yong Hu
Format:	Article
Language:	English
Published:	BMC 2022-05-01
Series:	Journal of Nanobiotechnology
Online Access:	https://doi.org/10.1186/s12951-022-01418-5

Similar Items

Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy
by: Wei Jiang, et al.
Published: (2022-03-01)

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity
by: Aleen Khoury, et al.
Published: (2022-04-01)

Platinum-crosslinking polymeric nanoparticle for synergetic chemoradiotherapy of nasopharyngeal carcinoma
by: Yuxun Ding, et al.
Published: (2021-12-01)

Delivery system designs for platinum prodrug in cancer treatment
by: Lim, Wei Qi
Published: (2019)

Potent Chlorambucil-Platinum(IV) Prodrugs
by: Angelico D. Aputen, et al.
Published: (2022-09-01)

Harnessing Nuclear Energy to Gold Nanoparticles for the Concurrent Chemoradiotherapy of Glioblastoma
by: Jui-Ping Li, et al.
Published: (2023-10-01)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
by: Xi-Lei Zhou, et al.
Published: (2021-05-01)

A bioconvergence study on platinum-free concurrent chemoradiotherapy for the treatment of HPV-negative head and neck carcinoma
by: Alessandra Gonnelli, et al.
Published: (2024-12-01)

Platinum Plus Tegafur–Uracil versus Platinum Alone during Concurrent Chemoradiotherapy in Patients with Nonmetastatic Nasopharyngeal Carcinoma: A Propensity-Score-Matching Analysis
by: Ching-Feng Lien, et al.
Published: (2022-09-01)

Repurposing Platinum(IV) Prodrugs to Modulate Mitochondrial Metabolism
by: Emmanouil Zacharioudakis, et al.
Published: (2023-07-01)

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
by: Jingjing Huang, et al.
Published: (2022-06-01)

Polymeric Nanoparticles with ROS‐Responsive Prodrug and Platinum Nanozyme for Enhanced Chemophotodynamic Therapy of Colon Cancer
by: Ying Hao, et al.
Published: (2020-10-01)

Bronchopleural Fistula After Concurrent Chemoradiotherapy
by: Jorien M. van de Pas, MD, et al.
Published: (2020-05-01)

A Platinum(IV) Prodrug—Perfluoroaryl Macrocyclic Peptide Conjugate Enhances Platinum Uptake in the Brain
by: Fadzen, Colin M, et al.
Published: (2021)

Fluorogenic platinum(iv) complexes as potential predictors for the design of hypoxia-activated platinum(iv) prodrugs
by: Marsh, J, et al.
Published: (2024)

Cell-permeable lanthanide-platinum(IV) anti-cancer prodrugs
by: Yao, K, et al.
Published: (2021)

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
by: Suntharalingam, Kogularamanan, et al.
Published: (2017)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
by: Jiraporn Setakornnukul, et al.
Published: (2018-03-01)

Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer
by: Zhang R, et al.
Published: (2017-09-01)

A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence
by: Qi Liu, et al.
Published: (2020-04-01)

Prodrug Approach: NSAID Conjugates of Platinum Compounds as Anti-Cancer Agents
by: NIJA B
Published: (2023-12-01)

Editorial: The role of platinum-based antitumor prodrugs in medicinal inorganic chemistry
by: Nicola Margiotta, et al.
Published: (2023-03-01)

Concurrent chemoradiotherapy in adjuvant treatment of breast cancer
by: Erraki Abdelouahed, et al.
Published: (2009-04-01)

Efficacy of Concurrent Chemoradiotherapy Combined with rhAd-p53 on Locally Advanced Cervical Cancer
by: DONG Yaqin, et al.
Published: (2021-10-01)

Correction to: Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer
by: Hyera Kim, et al.
Published: (2020-07-01)

Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study
by: Yuanxiu Yin, et al.
Published: (2022-07-01)

Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial
by: Jie Chen, et al.
Published: (2022-07-01)

Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents
by: Angelico D. Aputen, et al.
Published: (2023-04-01)

Self-assembly nanoplatform of platinum (Ⅳ) prodrug for enhanced ovarian cancer therapy
by: Xiao Ma, et al.
Published: (2023-08-01)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
by: Philipp Fronik, et al.
Published: (2022-04-01)

Potentialities of multi-b-values diffusion-weighted imaging for predicting efficacy of concurrent chemoradiotherapy in cervical cancer patients
by: Bing Liu, et al.
Published: (2020-08-01)

Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy
by: Yutaka Takahara, et al.
Published: (2022-12-01)

Self‐Cooperative Prodrug Nanovesicles Migrate Immune Evasion to Potentiate Chemoradiotherapy in Head and Neck Cancer
by: Yun Zhu, et al.
Published: (2022-12-01)

The clinical impact of supraclavicular lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
by: Yen-Hao Chen, et al.
Published: (2018-01-01)

Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis
by: Haonan Liu, et al.
Published: (2022-12-01)

A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx
by: Pei-Wei Huang, et al.
Published: (2018-04-01)

Adverse effects of chemoradiotherapy on invasion and metastasis of tumor cells
by: Wei Xiong, et al.
Published: (2020-09-01)

Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles
by: Min, Yuanzeng, et al.
Published: (2014)

Retrospective cohort study for thrombocytopenia during concurrent chemoradiotherapy for rectal cancer
by: Yue Teng, et al.
Published: (2024-01-01)

Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy
by: Li Tang, et al.
Published: (2019-12-01)